Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
IDRA > SEC Filings for IDRA > Form 8-K on 13-Jun-2014All Recent SEC Filings

Show all filings for IDERA PHARMACEUTICALS, INC.

Form 8-K for IDERA PHARMACEUTICALS, INC.


13-Jun-2014

Change in Directors or Principal Officers, Submission of Matters to a


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

In the first half of 2014, Idera Pharmaceuticals, Inc. (the "Company") significantly expanded its management team. As a result of related changes in authority and responsibility and changes in the Company's reporting structure, effective June 10, 2014, Dr. Timothy M. Sullivan, the Company's Vice President, Development Programs and Alliance Management, and Dr. Robert D. Arbeit, the Company's Vice President, Clinical Development, who will continue to serve in those positions, are no longer Section 16 officers or executive officers of the Company and will no longer be identified as named executive officers in its filings with the Securities and Exchange Commission (the "SEC").

The disclosure in Item 5.07 of this Current Report on Form 8-K is incorporated herein by reference.

(e)

At the Company's 2014 annual meeting of stockholders held on June 9, 2014 (the "Annual Meeting"), the Company's stockholders approved an amendment to the Company's 2013 Stock Incentive Plan (the "2013 Plan") to increase the number of shares authorized for issuance thereunder by 6,000,000 shares from (i) an aggregate of 4,224,460 shares of Common Stock plus such additional number of shares of Common Stock (up to 5,720,540 shares) as is equal to the number of shares of Common Stock subject to awards granted under the Company's 2008 Stock Incentive Plan (the "2008 Plan") which awards expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right (such additional shares being referred to as the "2008 Plan Potential Rollover Shares"), to
(ii) an aggregate of 10,224,460 shares of Common Stock plus the 2008 Plan Potential Rollover Shares. This amendment to the 2013 Plan had previously been approved by the Company's Board of Directors subject to stockholder approval.

The provisions of the 2013 Plan are described in the Company's definitive proxy statement on Schedule 14A filed with the SEC on April 30, 2014 under "Proposal Three - Amendment of 2013 Stock Incentive Plan." Such description of the 2013 Plan is qualified in its entirety by reference to the complete text of the 2013 Plan, as amended, a copy of which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated herein by reference.



Item 5.07. Submission of Matters to a Vote of Security Holders.

At the Annual Meeting, the Company's stockholders voted in the following manner with respect to the following proposals:

1. The following nominees were elected to the Company's Board of Directors as Class I directors for terms expiring at the 2017 annual meeting of stockholders.

                                                                   Broker Non-
                                        For          Withheld         Votes
           Dr. Kelvin M. Neu          32,052,811       346,139       25,474,836
           Mr. William S. Reardon     31,930,402       468,548       25,474,836


The terms of the following directors continued after the Annual Meeting:

Sudhir Agrawal, D. Phil Julian C. Baker Youssef El Zein James A. Geraghty Mark Goldberg, M.D.

Robert W. Karr, M.D.
Malcolm MacCoss, Ph.D.
Eve E. Slater, M.D.

As previously disclosed, C. Keith Hartley and Abdul-Wahab Umari did not stand for re-election at the Annual Meeting. Mr. Umari delivered a written resignation to the Company on June 9, 2014 confirming that he no longer serves as a director.

2. A non-binding, advisory proposal on the compensation of the Company's named executive officers was approved.

                         For:                  31,425,269
                         Against:                 831,867
                         Abstain:                 141,814
                         Broker Non-Votes:     25,474,836

3. The amendment to the Company's 2013 Plan was approved.

                         For:                  28,270,654
                         Against:               3,907,084
                         Abstain:                 221,212
                         Broker Non-Votes:     25,474,836

4. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2014 was ratified.

                         For:                  57,070,815
                         Against:                 408,799
                         Abstain:                 392,801
                         Broker Non-Votes:          1,371



Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

See attached Exhibit Index.


  Add IDRA to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for IDRA - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.